Table 2 Blood cytokine levels in Standard and Coated TKA (quantitative values given in pg/ml as median (quartiles), absolute (n) and relative (%) frequencies of values above 0.01 pg/ml). p-values: 1 Non allergy patients receiving standard TKA vs. non-allergy patients receiving coated TKA. 2 Allergy group vs. coated non-allergy group (all patients, Chi2-Test). 3 Allergy group vs. matched-pair group (Mann-Whitney U-Test)
Standard TKA [n = 35] | Coated TKA [n = 37] | Allergy [n = 8] | vs. Coated TKA | Non-Allergy Matched [n = 8] | vs. Allergy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
median | n | % | median | n | % | p-value1 | median | n | % | p-value2 | median | n | % | p-value3 | |
IL-1beta | |||||||||||||||
prior to surgery | 0 (0.0; 0.0) | 4 | 11.4 | 0 (0.0; 0.0) | 5 | 12.8 | 0.899 | 0 (0.0; 0.1) | 2 | 25 | 0.493 | 0 (0.0; 0.0) | 0 | 0 | 0.144 |
1 year follow-up | 0 (0.0; 0.0) | 2 | 5.7 | 0 (0.0; 0.0) | 1 | 2.5 | 0.609 | 0 (0.0; 0.0) | 0 | 0 | 0.717 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
3-year follow-up | 0 (0.0; 0.0) | 1 | 3.1 | 0 (0.0; 0.0) | 1 | 3.1 | 0.963 | 0 (0.0; 0.0) | 0 | 0 | 0.894 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
IL-5 | |||||||||||||||
prior to surgery | 0.1 (0.0; 0.4) | 30 | 85.7 | 0.2 (0.0; 0.4) | 29 | 74.4 | 0.427 | 0 (0.0; 0.1) | 5 | 63 | 0.125 | 0.05 (0.01; 0.33) | 6 | 75 | 0.455 |
1 year follow-up | 0.1 (0.0; 0.2) | 26 | 74.3 | 0.0 (0.1; 0.1) | 28 | 71.8 | 0.824 | 0 (0.0; 0.1) | 5 | 71 | 0.987 | 0.02 (0.0; 0.11) | 4 | 50 | 0.905 |
3-year follow-up | 0 (0.0; 0.0) | 1 | 3.1 | 0 (0.0; 0.0) | 0 | 0.0 | 0.329 | 0 (0.0; 0.0) | 0 | 0 | 0.539 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
IL-6 | |||||||||||||||
prior to surgery | 0 (0.0; 1.1) | 15 | 42.9 | 0 (0.5; 0.5) | 9 | 23.1 | 0.152 | 0 (0.0; 0.0) | 0 | 0 | 0.022 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
1 year follow-up | 0.4 (0.0; 4.7) | 18 | 51.4 | 1.8 (0.0; 4.9) | 24 | 61.5 | 0.239 | 0 (0.0; 4.3) | 3 | 43 | 0.401 | 1.7 (0.8; 3.5) | 6 | 75 | 0.8 |
3-year follow-up | 1.5 (0.0; 3.4) | 22 | 68.8 | 0.7 (0.1; 1.4) | 20 | 62.5 | 0.652 | 1.2 (0.0; 1.9) | 5 | 71 | 0.829 | 0.9 (0.2; 1.3) | 6 | 75 | 0.381 |
IL-8 | |||||||||||||||
prior to surgery | 6.2 (4.0; 9.2) | 34 | 97.1 | 6.7 (3.3; 9.8) | 38 | 97.4 | 0.952 | 6.0 (4.0; 29.6) | 7 | 88 | 0.548 | 8.2 (5.8; 14.5) | 8 | 100 | 0.674 |
1 year follow-up | 3.3 (0.0; 6.1) | 22 | 62.9 | 2.1 (0.0; 7.3) | 20 | 51.3 | 0.420 | 0 (0.0; 2.8) | 3 | 43 | 0.589 | 3.7 (0.0; 7.3) | 5 | 63 | 0.180 |
3-year follow-up | 5.4 (4.7; 9.0) | 32 | 100 | 5.8 (4.5; 6.7) | 31 | 96.9 | 0.298 | 4.6 (3.9; 6.4) | 7 | 100 | 0.539 | 5.9 (5.3; 6.6) | 8 | 100 | 0.325 |
IL-10 | |||||||||||||||
prior to surgery | 0.9 (0.8; 1.0) | 35 | 100 | 0.9 (0.8; 1.1) | 39 | 100 | n.a. | 1.1 (0.9; 1.2) | 8 | 100 | n.a. | 0.8 (0.7; 0.9) | 8 | 100 | 0.016 |
1 year follow-up | 0.9 (0.6; 1.1) | 35 | 100 | 0.8 (0.6; 1.0) | 39 | 100 | n.a. | 0.8 (0.6; 1.2) | 7 | 100 | n.a. | 0.7 (0.6; 0.8) | 8 | 100 | 0.487 |
3-year follow-up | 0 (0.0; 0.0) | 5 | 15.6 | 0 (0.0; 0.0) | 3 | 9.4 | 0.265 | 0 (0.0; 0.0) | 0 | 0 | 0.447 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
IFN γ | |||||||||||||||
prior to surgery | 0 (0.0; 0.0) | 3 | 8.6 | 0 (0.0; 0.0) | 11 | 28.2 | 0.606 | 1.8 (1.3; 2.6) | 8 | 100 | < 0.001 | 0 (0.0; 0.0) | 0 | 0 | < 0.001 |
1 year follow-up | 0 (0.0; 0.0) | 9 | 25.7 | 0 (0.0; 0.2) | 20 | 51.3 | 0.120 | 0.7 (0.1; 1.3) | 6 | 86 | 0.01 | 0 (0.0; 0.1) | 2 | 25 | 0.038 |
3-year follow-up | 0 (0.0; 0.0) | 0 | 0.0 | 0 (0.0; 0.0) | 1 | 3.1 | 0.298 | 0 (0.0; 0.0) | 0 | 0 | 0.539 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
TNF α | |||||||||||||||
prior to surgery | 0 (0.0; 0.0) | 5 | 14.3 | 0 (0.0; 0.0) | 6 | 15.4 | 0.825 | 0 (0.0; 0.1) | 2 | 25 | 0.597 | 0 (0.0; 0.0) | 0 | 0 | 0.144 |
1 year follow-up | 0 (0.0; 0.0) | 2 | 5.7 | 0 (0.0; 0.0) | 1 | 2.6 | 0.609 | 0 (0.0; 0.0) | 0 | 0 | 0.717 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |
3-year follow-up | 0 (0.0; 0.0) | 1 | 3.1 | 0 (0.0; 0.0) | 1 | 3.1 | 0.963 | 0 (0.0; 0.0) | 0 | 0 | 0.894 | 0 (0.0; 0.0) | 0 | 0 | 1.0 |